Carmen Stecher

Dr. Carmen Stecher

Medical University of Vienna, Vienna, Wien, Austria
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Immunity
Verified
Journal Article
Closed access
DHDietmar Herndler-Brandstetter
Dietmar Herndler-Brandstetter
HIHarumichi Ishigame
Harumichi Ishigame
RSRyo Shinnakasu
Ryo Shinnakasu
VPValerie Plajer
Valerie Plajer
CSCarmen Stecher
Carmen Stecher
RFRichard A. Flavell
Richard A. Flavell

25 October 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DHDietmar Herndler-Brandstetter
Dietmar Herndler-Brandstetter
LSLiang Shan
Liang Shan
YYYi Yao
Yi Yao
CSCarmen Stecher
Carmen Stecher
VPValerie Plajer
Valerie Plajer
RFRichard A. Flavell
Richard A. Flavell
Significance: Humanized mice represent a promising approach to study the human immune system in health and disease. However, insufficient development and function of human lymphocytes limit the applicability of humanized mice for cancer biology and therapy. We demonstrate that humanSIRPAandIL15knock-in (SRG-15) mice support efficient development of circulating and tissue-resident natural killer (NK) cells, intraepithelial lymphocytes, and innate lymphoid cell subsets. In contrast to previous humanized mouse models, human NK cells in SRG-15 mice mediate efficient antibody-dependent cellular cytotoxicity and thereby enable NK cell-targeted cancer immunotherapy of tumor xenografts. As such, SRG-15 humanized mice may facilitate translational research by enabling the development of novel NK and CD8+T cell-based therapeutic approaches that target human infections and malignancies.

22 May 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
CSCarmen Stecher
Carmen Stecher
CBClaire Battin
Claire Battin
JLJudith Leitner
Judith Leitner
MZMarkus Zettl
Markus Zettl
KGKatharina Grabmeier-Pfistershammer
Katharina Grabmeier-Pfistershammer
PSPeter Steinberger
Peter Steinberger
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy. However, current immune checkpoint-based therapies are successful only in a subset of patients, and acquired resistances pose additional challenges. Finding new targets and combining checkpoint inhibitors might help to overcome these limitations. In this study, human T cells stimulated with allogeneic DC were used to compare immune checkpoint inhibitors targeting TIM-3, BTLA, LAG-3, CTLA 4 and TIGIT alone or in combination with a PD-1 antibody. We found that PD-1 blockade bears a unique potency to enhance T cell proliferation and cytokine production. Other checkpoint inhibitors failed to significantly augment T cell responses when used alone. However, antibodies to TIM 3, BTLA, LAG 3 and CTLA 4 enhanced T cell proliferation in presence of a PD-1 antibody. Upregulation of coinhibitory T cell receptors upon PD 1 blockade was identified as a potential mechanism for synergistic effects between checkpoint inhibitors. Donor-specific variation in response to immune checkpoint inhibitors was attributed to the T cells rather than DC. Additionally, we analyzed the regulation of checkpoint molecules and their ligands on T cells and allogeneic DC in co-culture, which suggested a PD-1 blockade dependent crosstalk between T cells and APC. Our results indicate that several immune checkpoint inhibitors have the capacity to enhance T cell responses when combined with PD-1 blockade. Additional in vitro studies on human T cells will be useful to identify antibody combinations with the potential to augment T cell responses in cancer patients.

1 October 2017 in Clinical Immunology
Verified
Journal Article
Closed access
KGKatharina Grabmeier-Pfistershammer
Katharina Grabmeier-Pfistershammer
CSCarmen Stecher
Carmen Stecher
MZMarkus Zettl
Markus Zettl
SRSandra Rosskopf
Sandra Rosskopf
ARArmin Rieger
Armin Rieger
PSPeter Steinberger
Peter Steinberger

2 September 2020 in Transplantation
Verified
Journal Article
Closed access
OROliver Robak
Oliver Robak
MKMarie-Theres Kastner
Marie-Theres Kastner
CSCarmen Stecher
Carmen Stecher
MSMartina Schneider
Martina Schneider
MAMartin Andreas
Martin Andreas
CSChristoph Steininger
Christoph Steininger
Background.: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with hematologic diseases but is associated with high mortality and morbidity. Cytomegalovirus (CMV) infection is common in HSCT patients and modulates vitamin D metabolism in vitro. We aimed at validating CMV-associated vitamin D metabolism in vivo in HSCT. Methods.: Patients treated for significant CMV viremia after HSCT were evaluated for CMV load before, during, and after antiviral treatment. RNA was isolated from whole-blood samples to test for regulation of key components of the vitamin D receptor (VDR) pathway during different phases of CMV viremia. Results.: CMV viremia developed a mean time of 102 (±34) d post-HSCT. Maximum levels of CMV-DNA reached a mean of 5668 (±7257) copies/mL. VDR expression was downregulated to a mean of 64.3% (±42.5%) relative to the VDR expression pre-CMV viremia (P = 0.035) and lagged in recovery following antiviral treatment. Toll-like receptor (TLR) 2 mRNA was upregulated to 225.4% during CMV viremia relative to the expression pre-CMV viremia (P = 0.012) but not TLR6/7/8 and the TLR-adaptor protein MyD88. Levels of 25-OH vitamin D were reduced in all viremic patients (48.0 ± 4.8 versus 25.1 ± 3.7 ng/mL) and were even lower after periods of CMV viremia compared with the control group (48.3 ± 3.5 versus 17.8 ± 1.8 ng/mL; P = 0.008). Conclusions.: CMV viremia is associated with significant dysregulation of vitamin D metabolism in HSCT patients.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSCarmen Stecher
Carmen Stecher
RBRomana Bischl
Romana Bischl
ASAnna Schmid-Böse
Anna Schmid-Böse
SFStefanie Ferstl
Stefanie Ferstl
EPElisabeth Potzmann
Elisabeth Potzmann
Dietmar Herndler-BrandstetterDietmar Herndler-Brandstetter
Dietmar Herndler-Brandstetter
Bone marrow (BM) mesenchymal stromal cells (MSC) provide microenvironmental niches that support hematopoietic stem cells and regulate hematopoiesis. Whether functional heterogeneity among BM MSCs contributes to the development and survival of distinct immune cell lineages remains incompletely understood. Here, we use an Il15 knockin reporter and multiple conditional deletion mouse models to show distinct differences in IL-15 expression between BM MSC subtypes. Conditional deletion of Il15 in Osx + stromal cells results in decreased natural killer (NK) cell precursors, memory CD8+ T cells and NKT cells but not mature NK cells. Lepr + stromal cells support the survival of mature NK cells and memory CD8+ T cells in the BM of older mice, while endothelial cells support mature NK cells and memory CD8+ T cells in the blood but not in the BM. Thus, our data suggest that MSC subtypes differentially regulate the development and survival of IL-15-dependent immune cell lineages in the BM.